Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes

Leukemia volume 17, pages 2101–2106 (2003)Cite this article

Abstract

The purpose of this study was to determine the efficacy of and tolerance to antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndrome (MDS). Therapy consisted of ATG 40 mg/kg/day daily intravenously (i.v.) for 4 days; cyclosporine daily orally for 6 months with levels titrated between 200 and 400 mg/dl; and methylprednisone 1 mg/kg i.v. daily before each dose of ATG. Of 32 patients treated, 31 patients were evaluable. The median age was 59 years (range, 28–79 years). A total of 18 patients had refractory anemia (RA) or RA with ringed sideroblasts (RARS), 10 patients had RA with excess blasts (RAEB), two patients had RAEB in transformation, and one patient had chronic myelomonocytic leukemia. ATG, cyclosporine, and methylprednisone induced complete (N=4) or partial (N=1) remission in five patients (16% of total; RA, two patients; RARS, two patients; and RAEB, one patient). Durable complete remissions were observed in three of 18 patients (17%) with RA (N=1) or RARS (N=2) (12, 41+, and 60+ months). The most common adverse events were fever and allergic reactions. Hepatic and renal dysfunction, albeit consistently reversible, occurred in 19 and 13% of the patients, respectively. In conclusion, an ATG-based regimen can produce durable complete remissions in a subset of patients with MDS.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  Google Scholar 

  2. Abruzzese E, Buss D, Rainer R, Rao PN, Pettanati MJ . Study of clonality in myelodysplastic syndromes: detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization. Leukemia Res 1996; 20: 551–557.

    Article  CAS  Google Scholar 

  3. Bernell P, Jacobsson B, Nordgren A, Hast R . Clonal cell lineage involvement in myelodysplastic syndromes studied by fluorescence in situ hybridization and morphology. Leukemia 1996; 10: 662–668.

    CAS  PubMed  Google Scholar 

  4. Coiffier B, Adeleine P, Viala JJ, Bryon PA, Fiere D, Gentilhomme O et al . Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients. Cancer 1983; 52: 83–90.

    Article  CAS  Google Scholar 

  5. Foucar K, Langdon II RM, Armitage JO, Olson DB, Carroll Jr TJ . Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985; 56: 553–561.

    Article  CAS  Google Scholar 

  6. Mufti GJ, Galton DA . Myelodysplastic syndromes: natural history and features of prognostic importance. Clin Haematol 1986; 15: 953–971.

    CAS  PubMed  Google Scholar 

  7. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408.

    CAS  PubMed  Google Scholar 

  8. Heaney ML, Golde DW . Myelodysplasia. N Engl J Med 1999; 340: 1649–1660.

    Article  CAS  Google Scholar 

  9. Kurzrock R, Talpaz M, Estey E, O'Brien S, Estrov Z, Gutterman JU . Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. Leukemia 1991; 5: 985–990.

    CAS  PubMed  Google Scholar 

  10. Kurzrock R, Cortes J, Thomas DA, Jeha S, Pilat S, Talpaz M . Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165–4172.

    Article  CAS  Google Scholar 

  11. Estey EH, Kurzrock R, Talpaz M, McCredie KB, O'Brien S, Kantarjian HM et al. Effects of low doses of recombinant human granulocyte–macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 1991; 77: 291–295.

    Article  CAS  Google Scholar 

  12. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82: 737–743.

    CAS  PubMed  Google Scholar 

  13. Ganser A, Volkers B, Greher J, Ottmann OG, Walther F, Becher R et al. Recombinant human granulocyte–macrophage colony-stimulating factor in patients with myelodysplastic syndromes – a phase I/II trial. Blood 1989; 73: 31–37.

    CAS  PubMed  Google Scholar 

  14. Vadhan-Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM et al. Effects of recombinant human granulocyte–macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545–1552.

    Article  CAS  Google Scholar 

  15. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87: 4076–4081.

    CAS  PubMed  Google Scholar 

  16. Hellstrom-Lindberg E, Negrin R, Stein R, Krantz S, Lindberg G, Vardiman J et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99: 344–351.

    Article  CAS  Google Scholar 

  17. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, Carlsson M, Carneskog J, Dahl IM et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythro-poietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68–75.

    CAS  PubMed  Google Scholar 

  18. Economopoulos T, Stathakis N, Foudoulakis A, Papadoulis N, Dervenoulas J, Papageorgiou E et al. Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification. Eur J Haematol 1987; 38: 338–344.

    Article  CAS  Google Scholar 

  19. de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 1995; 9: 1805–1811.

    CAS  PubMed  Google Scholar 

  20. Talpaz M, Zhang F, Kurzrock R . Myelodysplastic syndromes. Hemato–Oncol Clin Manage Modules 2001; 5: 1–27.

    Google Scholar 

  21. Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M . Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML)) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969–2977.

    CAS  PubMed  Google Scholar 

  22. Kurzrock R . Myelodysplastic syndrome overview. Semin Hematol 2002; 39: 18–25.

    Article  CAS  Google Scholar 

  23. Luger S, Sacks N . Bone marrow transplantation for myelodysplastic syndrome – who? when? and which? Bone Marrow Transplant 2002; 30: 199–206.

    Article  CAS  Google Scholar 

  24. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2440.

    Article  CAS  Google Scholar 

  25. Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, Herrmann F et al. Treatment of aplastic anemia with antithymocyte globulin and methylprednisolone with or without cyclosporine. N Engl J Med 1991; 324: 1297–1304.

    Article  CAS  Google Scholar 

  26. Rosenfeld SJ, Kimball J, Vining D, Young NS . Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85: 3058–3065.

    CAS  PubMed  Google Scholar 

  27. Young N, Griffith P, Brittain E, Elfenbein G, Gardner F, Huang A et al. A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 1988; 72: 1861–1869.

    CAS  PubMed  Google Scholar 

  28. Barrett J, Saunthararajah S, Molldrem J . Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15–29.

    Article  CAS  Google Scholar 

  29. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.

    CAS  PubMed  Google Scholar 

  30. Young NS, Maciejewski J . The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 1336: 1365–1372.

    Article  Google Scholar 

  31. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ . Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314–1322.

    Article  CAS  Google Scholar 

  32. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL . Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994; 84: 1620–1627.

    CAS  PubMed  Google Scholar 

  33. Biesma DH, van den Tweel JG, Verdonck LF . Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 1997; 79: 1548–1551.

    Article  CAS  Google Scholar 

  34. Sugawara T, Endo K, Shishido T, Sato A, Kameoka J, Fukuhara O et al. T cell-mediated inhibition of erythropoiesis in myelodysplastic syndromes. Am J Hematol 1992; 41: 304–305.

    Article  CAS  Google Scholar 

  35. Smith MA, Smith JG . The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leukemkia Res 1991; 15: 597–601.

    Article  CAS  Google Scholar 

  36. Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001; 112: 195–200.

    Article  CAS  Google Scholar 

  37. Tichelli A, Gratwohl A, Wuersch A, Nissen C, Speck B . Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 1988; 68: 139–140.

    Article  CAS  Google Scholar 

  38. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ . Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699–705.

    Article  CAS  Google Scholar 

  39. Jonasova A, Neuwirtova R, Cermak J, Vozobulova V, Mocikova K, Siskova M et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100: 304–309.

    Article  CAS  Google Scholar 

  40. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS . Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129–3133.

    Article  CAS  Google Scholar 

  41. Raghavachar A, Janssen JW, Schrezenmeier H, Wagner B, Bartram CR, Schulz AS et al. Clonal hematopoiesis as defined by polymorphic X-linked loci occurs infrequently in aplastic anemia. Blood 1995; 86: 2938–2947.

    CAS  PubMed  Google Scholar 

  42. Mortazavi Y, Chopra R, Gordon-Smith EC, Rutherford TR . Clonal patterns of X-chromosome inactivation in female patients with aplastic anaemia studies using a novel reverse transcription polymerase chain reaction method. Eur J Haematol 2000; 64: 385–395.

    Article  CAS  Google Scholar 

  43. Socie G . Could aplastic anaemia be considered a pre-pre-leukaemic disorder? Eur J Haematol Suppl 1996; 60: 60–63.

    CAS  PubMed  Google Scholar 

  44. Sole F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luno E et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 2000; 108: 346–356.

    Article  CAS  Google Scholar 

  45. de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, Tabak D, Abdelhay E . Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leukemia Res 2000; 24: 839–848.

    Article  CAS  Google Scholar 

  46. Bernasconi P, Alessandrino EP, Boni M, Bonfichi M, Morra E, Lazzarino M et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol 1994; 46: 270–277.

    Article  CAS  Google Scholar 

  47. Vila L, Charrin C, Archimbaud E, Treille-Ritouet D, Fraisse J, Felman P et al. Correlations between cytogenetics and morphology in myelodysplastic syndromes. Blut 1990; 60: 223–227.

    Article  CAS  Google Scholar 

  48. Maciejewski JP, Follmann D, Nakamura R, Saunthararajah Y, Rivera CE, Simonis T et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001; 98: 3513–3519.

    Article  CAS  Google Scholar 

  49. Young NS, Barrett AJ . The treatment of severe acquired aplastic anemia. Blood 1995; 85: 3367–3377.

    CAS  PubMed  Google Scholar 

  50. Hunter RF, Mold NG, Mitchell RB, Huang AT . Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. Proc Natl Acad Sci USA 1985; 82: 4823–4827.

    Article  CAS  Google Scholar 

  51. Huang AT, Mold NG . The role of CD45RO in antithymocyte globulin's stimulation of primitive haemopoietic cells. Br J Haematol 1994; 88: 643–646.

    Article  CAS  Google Scholar 

  52. Killick SB, Marsh JC, Gordon-Smith EC, Sorlin L, Gibson FM . Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 2000; 108: 582–591.

    Article  CAS  Google Scholar 

  53. Gluckman E, Esperou-Bourdeau H, Baruchel A, Boogaerts M, Briere J, Donadio D et al. Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. Blood 1992; 79: 2540–2546.

    CAS  PubMed  Google Scholar 

  54. Marsh J, Schrezenmeier H, Marin P, Ilhan O, Ljungman P, McCann S et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 1999; 93: 2191–2195.

    CAS  PubMed  Google Scholar 

  55. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156–163.

    Article  Google Scholar 

  56. Mineishi S, Filippa D, Childs B, Castro-Malaspina H . Hypoplastic myelodysplastic syndrome (MDS): clinical, hematologic, and pathologic observations in 36 cases. Blood 1994; 84: 315a.

    Google Scholar 

  57. List AF, Glinsmann-Gibson B, Spier C, Taetle R In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes (MDS): identification of a hypocellular subset responsive to immune suppression. Blood 1992; 80: 28a.

    Google Scholar 

  58. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith JC, Taetle R . A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 2003; 120: 679–684.

    Article  CAS  Google Scholar 

  59. Bielory L, Gascon P, Lawley TJ, Young NS, Frank MM . Human serum sickness: a prospective analysis of 35 patients treated with equine anti-thymocyte globulin for bone marrow failure. Medicine 1988; 67: 40–57.

    Article  CAS  Google Scholar 

  60. Doney K, Pepe M, Storb R, Bryant E, Anasetti C, Appelbaum FR et al. Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high-dose methylprednisolone, and oxymetholone. Blood 1992; 79: 2566–2571.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    S Yazji, F J Giles, A-M Tsimberidou, E H Estey, H M Kantarjian, S A O'Brien & R Kurzrock

  2. Department of Bioimmunotherapy, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

    S Yazji, F J Giles, A-M Tsimberidou, E H Estey, H M Kantarjian, S A O'Brien & R Kurzrock

Authors
  1. S Yazji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F J Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A-M Tsimberidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E H Estey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H M Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S A O'Brien
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Kurzrock
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

There was no research support for this study

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yazji, S., Giles, F., Tsimberidou, AM. et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17, 2101–2106 (2003). https://doi.org/10.1038/sj.leu.2403124

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403124

Keywords

This article is cited by

Search

Advanced search

Quick links